Larvol Delta - BlossomHill-Therapeutics-to-Present-Updated-Data-from-Ongoing-Phase-12-SOLARA-Trial-of-its-Macrocyclic-OMNIEGFR-Inhibitor-BH30643-in-EGFRmutant-NSCLC-at-the-2026-World-Conference-on-Lung-Cancer

BH-30643 - BlossomHill Therap

https://www.tradingview.com/news/tradingview:8a4140bc68902:0-blossomhill-reports-45-orr-88-dcr-for-bh-30643-in-c797s-positive-nsclc-phase-2-planned/

Sep 15, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Next